Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3641388 | 0.93 | ACACB (0.41) | LMNACYP2D6CYP2C9CHRM2POLB | |
| SCHEMBL3014990 | 0.93 | ACACB (0.41) | LMNACYP2D6CYP2C9CHRM2POLB | |
| SCHEMBL13266922 | 0.93 | MCHR1 (0.43) | LMNACYP2D6CYP2C9HRH3POLB | |
| SCHEMBL3015746 | 0.92 | KMT2A (0.42) | KMT2A | |
| SCHEMBL13984836 | 0.86 | POLB (0.42) | LMNACYP2D6CYP2C9POLBPIN1 | |
| SCHEMBL3018006 | 0.85 | KMT2A (0.40) | PIN1KMT2AACACB | |
| SCHEMBL3012552 | 0.85 | CASP3 (0.43) | PIN1KMT2A | |
| SCHEMBL13267312 | 0.85 | KMT2A (0.44) | LMNAHRH3KDM4EKMT2A | |
| SCHEMBL3015812 | 0.85 | KMT2A (0.44) | PIN1KMT2AACACB | |
| SCHEMBL3802721 | 0.85 | KMT2A (0.44) | PIN1KMT2AACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617256-B2 | Antibacterial agents | ACHAOGEN, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20170088549-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2017-03-30 | — | — | US | disclosed |
| EP-2662353-A2 | Antibacterial agents | Achaogen, Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088549-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, ABCB11 | LMNA 3214/4885CYP2D6 30/4885CYP2C9 62/4885 |
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, ABCB11 | LMNA 3214/4885CYP2D6 30/4885CYP2C9 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.